

Figure 1




Figure 2




Figure 3





Figure 4

FIGURE 5

	CDRI
1-1 14/1 Vha?	MC TV" TCT GGA GAT ANA TTU GGA GAT ANA TAT GCT THE THE THE THE CAB AND ICA ONE CAD THE CCT EFFO OFFE AND TAT CAN GAT AND TAT. T
1-1 16/9 VAOT	240 155 C CAU GCT ATG GAT GAO GCT GAC TAT TAC T
1-1 11/9 VAO3	60 75 10 105 110 115 115 115 116 110 110 110 110 110 110 110 110 110
3-1 1479 VAO3	240 CAG GCT ATG GAT GAG BCT GAC T
1-10 PP 05	
1.10 PF 05	240 GCC CAS GNG GAG
2-14 FP 14	40 75 100 105 110 110 110 110 110 110 110 11
2-14 PP 14	115 MA A ACC ACC ACT CTC
1-19 7P 03	τοτ σας πες
3-19 PP 02	755 6CT CAG GGG GAA GAT GAG GGT GAC TAT TI A
2-21 SORT 06	40 15 150 150 150 150 150 150 150 150 150
3-23 SORT D4	דר, כשב פשא פשם אכב אאם רדם אכה פדר דד פשב פשא פשם אכב אאב רדם אכב פדר

Somatic hypermutation in translocus V genes

No of Mutations




Lambda chain

Kappa chain

Heavy chain

Human antibody responses in 5-feature (H. κ . λ) Translocus mice



7783.26 from a 5-feature translocus mouse A human IgM,λ monoclonal anti-human PLAP

